Cardiometabolic-Sleep Comorbidity Treatment Global Market Report 2026

The cardiometabolic-sleep comorbidity treatment market size has grown rapidly in recent years. It will grow from $6.25 billion in 2025 to $6.94 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to rising prevalence of obstructive sleep apnea and obesity, growing awareness of cardiometabolic disorders, adoption of positive airway pressure devices, expansion of hospital and sleep clinic networks, increasing focus on lifestyle interventions.

The cardiometabolic-sleep comorbidity treatment market size is expected to see rapid growth in the next few years. It will grow to $10.58 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing adoption of AI-based risk scoring and predictive analytics, increasing integration of telemonitoring platforms, rising demand for combination pharmacotherapies, expansion of personalized care-management services, growing emphasis on patient education and adherence programs. Major trends in the forecast period include increasing adoption of wearable sleep and cardiometabolic monitoring devices, rising demand for personalized lifestyle and care-management programs, growing integration of telemonitoring and remote risk stratification, expansion of multi-disorder therapeutic approaches, rising focus on weight-loss pharmacotherapy and medication optimization.

The rising prevalence of cardiometabolic disorders is anticipated to fuel the expansion of the cardiometabolic sleep comorbidity treatment market over the forecast period. Cardiometabolic disorders consist of a cluster of interconnected conditions, including cardiovascular diseases, type 2 diabetes, obesity, and metabolic syndrome, all of which markedly elevate the risk of heart disease, stroke, and long-term metabolic complications. The escalating burden of these disorders is influenced by multiple factors such as poor dietary habits, sedentary lifestyles, aging populations, and rising obesity rates. Cardiometabolic-sleep comorbidity treatments target the strong bidirectional link between sleep disorders by simultaneously managing sleep disturbances and metabolic abnormalities. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, cardiovascular disease caused 919,032 deaths in the United States in 2023, accounting for roughly one in every three deaths. Coronary heart disease remained the most common type of cardiovascular disease, with nearly one in six related deaths occurring among adults under 65. Hence, the increasing prevalence of cardiometabolic disorders is driving the growth of the cardiometabolic sleep comorbidity treatment market.

Leading companies operating in the cardiometabolic sleep comorbidity treatment market are focusing on developing innovative solutions, such as targeted pharmacotherapies, to simultaneously manage obesity, metabolic disorders, and obstructive sleep apnea. Targeted pharmacotherapies are medications designed to act on specific biological pathways or disease mechanisms to treat particular conditions more effectively with fewer side effects. For example, in December 2024, Eli Lilly and Company, a US-based pharmaceutical company, received U.S. Food and Drug Administration approval for Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity, marking the first pharmacological therapy specifically authorized for this condition. The approval was based on clinical trial data demonstrating significant reductions in apnea-hypopnea events and meaningful weight loss among patients using the drug alongside lifestyle interventions. This milestone provides a new treatment option for patients who struggle with conventional therapies such as continuous positive airway pressure, expanding the management strategies available for obstructive sleep apnea.

In June 2025, DarioHealth Corp., a US-based digital health company that delivers cardiometabolic-sleep comorbidity treatments, partnered with GreenKey Health to expand their sleep health program. Through this partnership, they aim to improve the management of sleep disorders and cardiometabolic comorbidities by combining DarioHealth’s AI-driven behavioral and chronic disease management platform with GreenKey Health's expertise in obstructive sleep apnea (OSA) diagnosis, remote monitoring, and telehealth services. GreenKey Health LLC is a US-based digital health company focused on sleep health solutions, including diagnostic services, remote patient monitoring, and wearable alternatives to continuous positive airway pressure therapy.

Major companies operating in the cardiometabolic-sleep comorbidity treatment market are Pfizer Inc, Sanofi S.A, Novartis AG, Eli Lilly & Company, Novo Nordisk A/S, Medtronic PLC, Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co Ltd., AstraZeneca PLC, Omron Healthcare Co. Ltd., ResMed Inc., Dexcom Inc., Teladoc Health Inc., Fisher Paykel Healthcare Corporation Limited, BioSerenity SA, BMC Medical Co Ltd, CardiacSense Ltd, Compumedics Ltd.

North America was the largest region in the cardiometabolic-sleep comorbidity treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic-sleep comorbidity treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiometabolic-sleep comorbidity treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiometabolic-sleep comorbidity treatment market consists of revenues earned by entities by providing services such as continuous positive airway pressure (CPAP) therapy services, weight management and lifestyle intervention programs, diagnostic and monitoring services, telehealth and remote patient monitoring, combination therapy programs, and patient education and coaching services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic-sleep comorbidity treatment market also includes sales of positive airway pressure (PAP) and sleep apnea devices, weight loss pharmacotherapy, hypertension and diabetes medications, digital therapeutics & remote monitoring platforms, and sleep targeted pharmacological treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiometabolic-sleep comorbidity treatment involves medical approaches designed to concurrently manage coexisting sleep disorders and cardiometabolic conditions such as obesity, diabetes, hypertension, and cardiovascular disease. These treatments aim to enhance both sleep quality and metabolic health through lifestyle changes, pharmacological interventions, and, when required, medical devices or procedural support.

The essential treatment components of cardiometabolic-sleep comorbidity management include positive airway pressure therapy and sleep apnea devices, weight-loss pharmacotherapy, hypertension or diabetes medication optimization programs, remote monitoring and risk stratification analytics, and lifestyle and care-management services. Positive airway pressure therapy and sleep apnea devices are designed to maintain airway patency during sleep and improve cardiometabolic outcomes. Comorbidity pathways include obstructive sleep apnea and obesity management, obstructive sleep apnea with hypertension or cardiovascular risk control, obstructive sleep apnea with type-2 diabetes management, heart failure with sleep-disordered breathing, and other metabolic sleep phenotypes. Therapeutic areas cover obstructive sleep apnea with cardiometabolic disorders, insomnia with cardiometabolic disorders, restless leg syndrome with cardiometabolic disorders, and other sleep disorders with cardiometabolic comorbidities, serving hospitals, cardiometabolic clinics, sleep clinics, durable medical equipment networks, retail pharmacies, and payers or population health managers.

Tariffs on imported medical devices, wearable monitors, and pharmacological agents are impacting the cardiometabolic-sleep comorbidity treatment market by increasing costs for positive airway pressure devices, telemonitoring platforms, and weight-loss drugs. Regions such as North America, Europe, and Asia-Pacific, which rely heavily on imported medical equipment and therapeutics, are most affected. While tariffs elevate procurement costs, they also promote local manufacturing, stimulate regional innovation in cost-effective treatment solutions, and encourage domestic development of integrated care platforms, ultimately supporting market resilience.

The cardiometabolic-sleep comorbidity treatment market research report is one of a series of new reports that provides cardiometabolic-sleep comorbidity treatment market statistics, including cardiometabolic-sleep comorbidity treatment industry global market size, regional shares, competitors with a cardiometabolic-sleep comorbidity treatment market share, detailed cardiometabolic-sleep comorbidity treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiometabolic-sleep comorbidity treatment industry. This cardiometabolic-sleep comorbidity treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.